Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

Dual Co-Stimulation with CD28 and ICOS Enhances T Cell Activation and Optimizes CAR-T Cell Antitumor Activity

Jianghua Wu, Wenjing Luo, Lu Tang, Zhaozhao Chen, Jie Zhou, Chenggong Li, Wei Xiong, Heng Mei, Yu Hu

Blood (2023) 142 (Supplement 1): 2061.

https://doi.org/10.1182/blood-2023-181472

Published: 2023

Journal Articles

Interim Results of the Launch Study-a Multicenter, Open-Label Study of Selinexor, Dexamethasone and Chemotherapy Drugs in Relapsed/ Refractory Multiple Myeloma

Chunyan Sun, Baijun Fang, Guangxun Gao, Fuling Zhou, Aili He, Fei Zhao, Junying Li, Chun Zhang, Li Weiming, Hui Cheng, Huili Cai, Bin Chen, Jingming Guo, Yu Hu

Blood (2023) 142 (Supplement 1): 4763.

https://doi.org/10.1182/blood-2023-186220

Published: 2023

Journal Articles

Quantification of ADA of Humanized CD19 CAR-T Cell Therapy in R/R LBCL

Zhongpei Huang, Heng Mei, Chenggong Li, Yu Hu

Blood (2023) 142 (Supplement 1): 6870.

https://doi.org/10.1182/blood-2023-188349

Published: 2023

Journal Articles

Recommendations on Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Combination of All- Trans Retinoic Acid and Arsenic Trioxide

Blood (2023) 142 (Supplement 1): 2946.

https://doi.org/10.1182/blood-2023-184433

Published: 2023

Journal Articles

Evaluating Effectiveness and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia in (CML-CP) without Optimal Response (Warning, Failure) to Imatinib or/and Dasatinib

Blood (2023) 142 (Supplement 1): 3171.

https://doi.org/10.1182/blood-2023-179142

Published: 2023

Journal Articles

Bio-Orthogonally Redirected Bispecific Lentiviral Vectors for In Vivo CAR-T Cell Generation

Heng Mei, Zhaozhao Chen, Yu Hu, Heng Mei

Blood (2023) 142 (Supplement 1): 2062.

https://doi.org/10.1182/blood-2023-181855

Published: 2023

Journal Articles

Pathophysiology and Treatment Opportunities of CX3CL1 in Liver Acute Gvhd

Ziwei Xu, Xiaoyan Zhao, Ziying Li, Yu Hu, Huafang Wang

Blood (2023) 142 (Supplement 1): 4946.

https://doi.org/10.1182/blood-2023-174808

Published: 2023

Journal Articles

Proteomics Reveals the Potential Pathogenesis of Coagulopathy in Patients with Hematological Malignancies Following CAR-T Therapy

Yingying Li, Jianghua Wu, Lili Luo, Yu Hu, Heng Mei

Blood (2023) 142 (Supplement 1): 1236.

https://doi.org/10.1182/blood-2023-179314

Published: 2023

Journal Articles

Gpibα Caar-T Cells Induce Autoreactive B Cells Elimination to Treat Immune Thrombocytopenia

Jie Zhou, Heng Mei, Yanyan Xu, Jinhui Shu, Linlin Huang, Min Xu, Haojie Jiang, Junling Liu, Yu Hu

Blood (2023) 142 (Supplement 1): 278.

https://doi.org/10.1182/blood-2023-172942

Published: 2023

Journal Articles

Integrin αvβ8-Mediated Activation of TGF-β1 Is Involved in Regulating the Sustained Response after TPO-Ras Withdrawal in ITP Patients

Min Xu, Jie Zhou, Jinhui Shu, Yu Hu, Heng Mei

Blood (2023) 142 (Supplement 1): 686.

https://doi.org/10.1182/blood-2023-181466

Published: 2023

Journal Articles

Targeting SIRT5 By Succinylating Hadha Synergizes with Venetoclax in Acute Myeloid Leukemia

Moran Wang, Wei Shi, Ruiqi Zhu, Donald Small, Li Li, Shengling Ma, Yu Hu

Blood (2023) 142 (Supplement 1): 4164.

https://doi.org/10.1182/blood-2023-178420

Published: 2023

Journal Articles

Inhibition of NOTCH4 Sensitizes FLT3/ITD Acute Myeloid Leukemia Cells to FLT3 Tyrosine Kinase Inhibition

Ruiqi Zhu, Courtney Shirley, Haihua Chu, Li Li, Bao Nguyen, Jaesung Seo, Tessa Seale, Amy Duffield, Louis M. Staudt, Mark J. Levis, Yu Hu, Donald Small

Blood (2023) 142 (Supplement 1): 5769.

https://doi.org/10.1182/blood-2023-190696

Published: 2023

Journal Articles

HIF-1α-Dependent Autophagy Deficiency in Bone Marrow Endothelial Progenitor Cells Contributes to Acute Graft-Versus-Host Disease after Allotransplant

Wenkai Zhang, Xie-Na Cao, Wei Shi, Linghui Xia, Li Li, Chun-Yan Sun, Yu Hu

Blood (2023) 142 (Supplement 1): 4794.

https://doi.org/10.1182/blood-2023-184413

Published: 2023

Journal Articles

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Blood (2023) 142 (Supplement 1): 869.

https://doi.org/10.1182/blood-2023-187740

Published: 2023

Journal Articles

Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF)

Blood (2023) 142 (Supplement 1): 1814.

https://doi.org/10.1182/blood-2023-179043

Published: 2023

Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin Lymphoma: Real-World Data in Chinese Population

Zixun Yan, Dehui Zou, Yuhua Li, Xiaojian Zhu, Dongmei Ji, Wenbin Qian, Ying Lu, Chunyan Ji, Keshu Zhou, Hongmei Jing, Hua Yang, Lanfang Li, Fei Li, Kailin Xu, Ting Niu, Depei Wu, Yu Hu, Weili Zhao

Blood (2023) 142 (Supplement 1): 6928.

https://doi.org/10.1182/blood-2023-181351

Published: 2023

Journal Articles

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation

Blood (2022) 140 (Supplement 1): 203–204.

https://doi.org/10.1182/blood-2022-170698

Published: 2022

Journal Articles

Allogeneic and Autologous Anti-CD7 CAR-T Cell Therapies in Relapsed or Refractory T Cell Malignancies

Yinqiang Zhang, Chenggong Li, Huiwen Jiang, Wenjing Luo, Mengyi Du, Fen Zhou, Lu Tang, Jianghua Wu, Qiuzhe Wei, Cong Lu, Haiming Kou, Di Wu, Chang Alex H, Heng Mei, Yu Hu

Blood (2022) 140 (Supplement 1): 4592–4594.

https://doi.org/10.1182/blood-2022-170819

Published: 2022

Journal Articles

BTK Inhibitors Improve CART19 Cell Therapy By Modulating Immune System

Wenjing Luo, Chenggong Li, Jianghua Wu, Yinqiang Zhang, Lu Tang, Mengyi Du, Xindi Wang, Wei Xiong, Haiming Kou, Cong Lu, Heng Mei, Yu Hu

Blood (2022) 140 (Supplement 1): 10294–10295.

https://doi.org/10.1182/blood-2022-170898

Published: 2022

Journal Articles

Multi-Omics Reveal Plasma Molecular Signatures of B-ALL Patients during CAR-T Cell Therapy

Jianghua Wu, Lu Tang, Mengyi Du, Chenggong Li, Haiming Kou, Huiwen Jiang, Wenjing Luo, Yinqiang Zhang, Zhongpei Huang, Danying Liao, Wei Xiong, Heng Mei, Yu Hu

Blood (2022) 140 (Supplement 1): 7384–7385.

https://doi.org/10.1182/blood-2022-166674

Published: 2022

NARROW

Dual Co-Stimulation with CD28 and ICOS Enhances T Cell Activation and Optimizes CAR-T Cell Antitumor Activity

Interim Results of the Launch Study-a Multicenter, Open-Label Study of Selinexor, Dexamethasone and Chemotherapy Drugs in Relapsed/ Refractory Multiple Myeloma

Quantification of ADA of Humanized CD19 CAR-T Cell Therapy in R/R LBCL

Recommendations on Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Combination of All- Trans Retinoic Acid and Arsenic Trioxide

Evaluating Effectiveness and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia in (CML-CP) without Optimal Response (Warning, Failure) to Imatinib or/and Dasatinib

Bio-Orthogonally Redirected Bispecific Lentiviral Vectors for In Vivo CAR-T Cell Generation

Pathophysiology and Treatment Opportunities of CX3CL1 in Liver Acute Gvhd

Proteomics Reveals the Potential Pathogenesis of Coagulopathy in Patients with Hematological Malignancies Following CAR-T Therapy

Gpibα Caar-T Cells Induce Autoreactive B Cells Elimination to Treat Immune Thrombocytopenia

Integrin αvβ8-Mediated Activation of TGF-β1 Is Involved in Regulating the Sustained Response after TPO-Ras Withdrawal in ITP Patients

Targeting SIRT5 By Succinylating Hadha Synergizes with Venetoclax in Acute Myeloid Leukemia

Inhibition of NOTCH4 Sensitizes FLT3/ITD Acute Myeloid Leukemia Cells to FLT3 Tyrosine Kinase Inhibition

HIF-1α-Dependent Autophagy Deficiency in Bone Marrow Endothelial Progenitor Cells Contributes to Acute Graft-Versus-Host Disease after Allotransplant

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF)

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin Lymphoma: Real-World Data in Chinese Population

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation

Allogeneic and Autologous Anti-CD7 CAR-T Cell Therapies in Relapsed or Refractory T Cell Malignancies

BTK Inhibitors Improve CART19 Cell Therapy By Modulating Immune System

Multi-Omics Reveal Plasma Molecular Signatures of B-ALL Patients during CAR-T Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only